OBJECTIVE: High-density lipoprotein (HDL) promotes reverse cholesterol transport from peripheral tissues to the liver for clearance. Reduced HDL-cholesterol (HDLc) is associated with atherosclerosis; however, as a predictor of cardiovascular disease, HDLc has limitations because it is not a direct marker of HDL functionality. Our objective was to develop a mass spectrometry-based method for the simultaneous measurement of HDLc and ApoAI kinetics in mice, using a single (2)H2O tracer, and use it to examine genetic and drug perturbations on HDL turnover in vivo. APPROACH AND RESULTS: Mice were given (2)H2O in the drinking water, and serial blood samples were collected at different time points. HDLc and ApoAI gradually incorporated (2)H, allowing experimental measurement of fractional catabolic rates and production rates for HDLc and ApoAI. ApoE(-/-) mice displayed increased fractional catabolic rates (P<0.01) and reduced production rates of both HDLc and ApoAI (P<0.05) compared with controls. In human ApoAI transgenic mice, levels and production rates of HDLc and human ApoAI were strikingly higher than in wild-type mice. Myriocin, an inhibitor of sphingolipid synthesis, significantly increased both HDL flux and macrophage-to-feces reverse cholesterol transport, indicating compatibility of this HDL turnover method with the macrophage-specific reverse cholesterol transport assay. CONCLUSIONS: (2)H2O-labeling can be used to measure HDLc and ApoAI flux in vivo, and to assess the role of genetic and pharmacological interventions on HDL turnover in mice. Safety, simplicity, and low cost of the (2)H2O-based HDL turnover approach suggest that this assay can be scaled for human use to study effects of HDL targeted therapies on dynamic HDL function.
OBJECTIVE: High-density lipoprotein (HDL) promotes reverse cholesterol transport from peripheral tissues to the liver for clearance. Reduced HDL-cholesterol (HDLc) is associated with atherosclerosis; however, as a predictor of cardiovascular disease, HDLc has limitations because it is not a direct marker of HDL functionality. Our objective was to develop a mass spectrometry-based method for the simultaneous measurement of HDLc and ApoAI kinetics in mice, using a single (2)H2O tracer, and use it to examine genetic and drug perturbations on HDL turnover in vivo. APPROACH AND RESULTS:Mice were given (2)H2O in the drinking water, and serial blood samples were collected at different time points. HDLc and ApoAI gradually incorporated (2)H, allowing experimental measurement of fractional catabolic rates and production rates for HDLc and ApoAI. ApoE(-/-) mice displayed increased fractional catabolic rates (P<0.01) and reduced production rates of both HDLc and ApoAI (P<0.05) compared with controls. In humanApoAItransgenic mice, levels and production rates of HDLc and humanApoAI were strikingly higher than in wild-type mice. Myriocin, an inhibitor of sphingolipid synthesis, significantly increased both HDL flux and macrophage-to-feces reverse cholesterol transport, indicating compatibility of this HDL turnover method with the macrophage-specific reverse cholesterol transport assay. CONCLUSIONS: (2)H2O-labeling can be used to measure HDLc and ApoAI flux in vivo, and to assess the role of genetic and pharmacological interventions on HDL turnover in mice. Safety, simplicity, and low cost of the (2)H2O-based HDL turnover approach suggest that this assay can be scaled for human use to study effects of HDL targeted therapies on dynamic HDL function.
Entities:
Keywords:
apolipoprotein A-I; cholesterol; deuterium oxide; lipoproteins, HDL; mass spectrometry; protein biosynthesis
Authors: Haihong Zhou; Wenyu Li; Sheng-Ping Wang; Vivienne Mendoza; Raymond Rosa; James Hubert; Kithsiri Herath; Theresa McLaughlin; Rory J Rohm; Michael E Lassman; Kenny K Wong; Douglas G Johns; Stephen F Previs; Brian K Hubbard; Thomas P Roddy Journal: J Lipid Res Date: 2012-03-03 Impact factor: 5.922
Authors: Anh Hoang; Brian G Drew; Hann Low; Alan T Remaley; Paul Nestel; Bronwyn A Kingwell; Dmitri Sviridov Journal: Eur Heart J Date: 2011-04-15 Impact factor: 29.983
Authors: Stephen F Previs; Richard Fatica; Visvanathan Chandramouli; James C Alexander; Henri Brunengraber; Bernard R Landau Journal: Am J Physiol Endocrinol Metab Date: 2003-12-23 Impact factor: 4.310
Authors: Ling Li; Gurkan Bebek; Stephen F Previs; Jonathan D Smith; Rovshan G Sadygov; Arthur J McCullough; Belinda Willard; Takhar Kasumov Journal: J Proteome Res Date: 2016-08-05 Impact factor: 4.466
Authors: Stela Z Berisha; Greg Brubaker; Takhar Kasumov; Kimberly T Hung; Patricia M DiBello; Ying Huang; Ling Li; Belinda Willard; Katherine A Pollard; Laura E Nagy; Stanley L Hazen; Jonathan D Smith Journal: J Lipid Res Date: 2015-01-05 Impact factor: 5.922
Authors: Kadambari Chandra Shekar; Ling Li; Erinne R Dabkowski; Wenhong Xu; Rogerio Faustino Ribeiro; Peter A Hecker; Fabio A Recchia; Rovshan G Sadygov; Belinda Willard; Takhar Kasumov; William C Stanley Journal: J Mol Cell Cardiol Date: 2014-07-01 Impact factor: 5.000
Authors: Sangeeta R Kashyap; Abdullah Osme; Serguei Ilchenko; Makan Golizeh; Kwangwon Lee; Shuhui Wang; James Bena; Stephen F Previs; Jonathan D Smith; Takhar Kasumov Journal: J Clin Endocrinol Metab Date: 2018-02-01 Impact factor: 5.958